Revolutionary Pill AD109: Hope for millions at sleep apnea!

Revolutionary Pill AD109: Hope for millions at sleep apnea!

USA - A newly developed drug for sleep apnea in tablet form could soon offer a groundbreaking treatment method. Scientists from Harvard University have published grandiose results from a phase III study that were achieved with the drug AD109. The study comprised over 600 patients and demonstrated significant improvements: the number of nocturnal breathing interruptions was reduced by almost 56 percent. This reports Exxpress.at .

The drug contains the active ingredients of aroxybutynin and atomoxetine and is taken before going to bed. The active ingredients aim to prevent the tongue muscles from sleeping and to support nerve activity in the throat. Over 22 percent of the subjects treated were able to achieve complete control of their sleep apnea, which exceeded the researchers' expectations.

Positive results of the synairgy study

like apnimed.com , the synairgy study was carried out as randomized, double blind, placebo-controlled study with 646 participants from 73 centers in the USA and Canada. The results showed that 51.2 percent of the participants had a significant reduction in the severity of obstructive sleep apnea (OSA). After 26 weeks, the reduction of the Apnoe Hypopnea index (AHI) was 55.6 percent, which was statistically significant (p = 0.001). AD109 proved to be well tolerated, without serious side effects

The application for admission to the US Medicines Authority FDA is planned for early 2026. Apnimed assumes that the results of a second, currently running phase III study will be available until the application.

challenges in the treatment of sleep apnea

sleep apnea is a chronic illness that affects an estimated 80 million people in the United States and one billion worldwide. Many remain undiagnosed, whereby it is necessary to expand the treatment options. Previous therapies such as CPAP masks or tongue pacemakers are widespread, but do not always show the desired effectiveness. In addition, compliance is often a problem with these methods and there is high variability in the therapy response.

innovations such as AD109 could be a promising alternative. There are also new approaches to the classification and therapy of sleep -related breathing disorders (SBAS). Newer metrics such as the arousal threshold and sleep apnea -specific hypoxemic load gain importance in the assessment of the severity and risk of sleep apnea. According to ncbi.nih.gov , individual therapeutic approaches must be taken into account, whereby interdisciplinary strategies and a good patient approach are decisive.

Developments in sleep medicine have gained speed due to the Covid 19 pandemic. This is also evident in the increasing use of new technologies such as telemedicine and outpatient sleep diagnostics.